69.18MMarket Cap3.76P/E (TTM)
1.300High1.280Low87.15KVolume1.290Open1.285Pre Close112.04KTurnover0.22%Turnover Ratio2.98P/E (Static)54.05MShares1.89052wk High0.86P/B51.80MFloat Cap0.99852wk Low--Dividend TTM40.47MShs Float23.639Historical High--Div YieldTTM1.56%Amplitude0.680Historical Low1.285Avg Price1Lot Size
Spero Therapeutics Stock Forum
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics announced a poster presentation at IDWeek 2024 showcasing in vitro data on SPR719, the active moiety of SPR720, for treating nontuberculous mycobacterium pulmonary disease (NTM-PD). The study, conducted with Microbiologics, revealed:
1. SPR719's low propensity for resistance d...
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fl...
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!
Gonna be looking for under 1.3 to hop on. However, 9 days until their P2 trial concludes. If momentum builds, it may push it really high before then plummet after. Or, as I am hoping, it sinks until the news drops and gets a temp boost.
Right now, it looks likely to drop due to the MACD death cross.. we shall see
In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the...
No comment yet